Drug Development (Granulocyte)

Drug Enables European Cancer Patients To Avoid BM Transplant

Published in Blood Weekly, April 14th, 1997

Rhone-Poulenc Rorer Inc., Aix-Les-Bains, France, announced that the European Commission has granted a marketing authorization for Granocyte (lenograstim) for use in peripheral blood progenitor cell (PBPC) mobilization for autologous transplantation.

The data was released at the 23rd Annual European Blood and Marrow Transplantation (EBMT) meeting. The authorization was granted through the European Mutual Recognition Procedure, a regulatory process designed and intended to speed up the review of a new drug that has been already approved in one EU country.

It was granted on the basis of several studies using Granocyte for PBPC mobilization. Granocyte...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1997-04-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry